Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Special Reports
The top 10 drugs losing US exclusivity in 2024
The unrelenting churning of time means many things to many people. For pharma execs, it’s a constant reminder of the need for new launches to supplant old meds.
Eric Sagonowsky
,
Fraiser Kansteiner
,
Zoey Becker
,
Angus Liu
,
Kevin Dunleavy
Mar 11, 2024 3:00am
Amid launch hurdles, Eisai updates Leqembi's sales forecast
Mar 7, 2024 11:29am
Eisai's Leqembi launch tripped up on a host of challenges
Feb 27, 2024 9:20am
Sage 'highly encouraged' by Zurzuvae launch with Biogen
Feb 14, 2024 1:21pm
Biogen slapped with DOJ subpoena over foreign operations
Feb 14, 2024 10:58am
Biogen CEO plots turnaround after 'weak' 2023 performance
Feb 13, 2024 11:28am